Compare Becton Dickinson and Co (BDX) vs W W Grainger Inc (GWW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs W W Grainger Inc — how do they compare? Becton Dickinson and Co trades at $154.42 (market cap $41.51B), while W W Grainger Inc trades at $1,365.27 (market cap $64.73B). The key difference: W W Grainger Inc is the larger of the two by market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | GWW | |
|---|---|---|
Market Cap | $41.51B | $64.73B |
Sector | Health | Technology |
52-Week High | $185.39 | $1.39K |
52-Week Low | $135.49 | $918.18 |
Enterprise Value | $57.97B | $66.82B |
Dividend Yield | 2.79% | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
GWW trades at $1,391.68, up 1.16% today, with a bullish technical outlook supported by moving averages and strong momentum. The company reported Q1 2026 EPS of $11.65, beating estimates, and raised its full-year guidance. Revenue growth remains steady, with 2026 revenue projected at $18.4B, while profitability metrics like ROE of 48.1% and net margin near 10% highlight operational strength. Positive analyst sentiment and recent dividend declarations reinforce investor confidence amid a favorable market backdrop.
The outlook for GWW is positive, driven by earnings beats and raised guidance, though valuation multiples like a P/E of 36.87 suggest premium pricing. Risks include economic sensitivity and competitive pressures, but institutional buy ratings and technical support near $1,380 provide a cushion for upward momentum if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →
